Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Chromadex Corp’s stock clocked out at $7.69, down -10.06% from its previous closing price of $8.55. In other words, the price has decreased by -$10.06 from its previous closing price. On the day, 2.35 million shares were traded.
Ratios:
To gain a deeper understanding of CDXC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.29. For the most recent quarter (mrq), Quick Ratio is recorded 3.06 and its Current Ratio is at 3.57. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.
On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when Jaksch Frank L Jr sold 37,161 shares for $6.19 per share. The transaction valued at 229,956 led to the insider holds 244,179 shares of the business.
Frank Jaksch Jr. bought 37,161 shares of CDXC for $229,961 on Dec 13 ’24. On Nov 22 ’24, another insider, Pamir Ozan, who serves as the Chief Financial Officer of the company, bought 2,907 shares for $7.36 each. As a result, the insider paid 21,397 and bolstered with 2,907 shares of the company.
Valuation Measures:
As of this moment, Chromadex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 73.03, and their Forward P/E ratio for the next fiscal year is 43.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.00 while its Price-to-Book (P/B) ratio in mrq is 12.90.
Stock Price History:
Over the past 52 weeks, CDXC has reached a high of $9.18, while it has fallen to a 52-week low of $1.57. The 50-Day Moving Average of the stock is 34.69%, while the 200-Day Moving Average is calculated to be 74.03%.
Shares Statistics:
A total of 77.33M shares are outstanding, with a floating share count of 49.23M. Insiders hold about 36.68% of the company’s shares, while institutions hold 29.21% stake in the company.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Chromadex Corp (CDXC) in the stock market.The consensus estimate for the next quarter is $0.02, with high estimates of $0.03 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.15 and $0.07 for the fiscal current year, implying an average EPS of $0.12. EPS for the following year is $0.2, with 3.0 analysts recommending between $0.25 and $0.14.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $27.09M. It ranges from a high estimate of $27.2M to a low estimate of $26.9M. As of the current estimate, Chromadex Corp’s year-ago sales were $22.15MFor the next quarter, 3 analysts are estimating revenue of $28.07M. There is a high estimate of $28.3M for the next quarter, whereas the lowest estimate is $27.8M.
A total of 3 analysts have provided revenue estimates for CDXC’s current fiscal year. The highest revenue estimate was $120.1M, while the lowest revenue estimate was $117.41M, resulting in an average revenue estimate of $118.67M. In the same quarter a year ago, actual revenue was $99.6MBased on 3 analysts’ estimates, the company’s revenue will be $143.43M in the next fiscal year. The high estimate is $148.4M and the low estimate is $138.3M.
